HOWL
Werewolf Therapeutics, Inc. NASDAQ Listed Apr 30, 2021$0.62
After hrs
$0.68
+0.31%
Mkt Cap $30.1M
52w Low $0.53
4.9% of range
52w High $2.38
50d MA $0.80
200d MA $1.06
P/E (TTM)
-0.6x
EV/EBITDA
0.3x
P/B
1.3x
Debt/Equity
0.4x
ROE
-245.2%
P/FCF
-0.5x
RSI (14)
—
ATR (14)
—
Beta
0.54
50d MA
$0.80
200d MA
$1.06
Avg Volume
386.6K
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
CIK (SEC)
Phone
617 952 0555
1030 Massachusetts Avenue · Watertown, MA 02138 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 0.65 | +2.6% | -4.6% | — | — | — | — | — |
| Mar 27, 2026 | AMC | -0.34 | -0.20 | +41.2% | 0.78 | -2.2% | +2.1% | +6.6% | +22.7% | +29.4% | +33.2% | — |
| Nov 4, 2025 | AMC | -0.39 | -0.36 | +7.7% | 1.21 | +2.5% | +0.8% | -0.8% | -5.0% | -4.1% | -6.6% | — |
| Aug 14, 2025 | AMC | -0.50 | -0.40 | +20.0% | 1.32 | -0.8% | +0.8% | +0.8% | -3.8% | -6.1% | -3.0% | — |
| May 8, 2025 | AMC | -0.44 | -0.40 | +9.1% | 0.87 | +0.0% | -8.1% | +14.9% | +17.2% | +13.8% | +27.6% | — |
| Mar 11, 2025 | AMC | -0.43 | -0.46 | -7.0% | 1.26 | +1.6% | -2.4% | -4.0% | -4.8% | -7.1% | -7.9% | — |
| Nov 7, 2024 | AMC | -0.41 | -0.38 | +7.3% | 2.24 | +3.1% | +2.7% | -1.8% | -4.0% | -8.5% | -13.8% | — |
| Aug 8, 2024 | AMC | -0.38 | -0.40 | -5.3% | 1.85 | -0.5% | +2.2% | +3.8% | +10.8% | +7.6% | +9.2% | — |
| May 3, 2024 | AMC | -0.35 | -0.39 | -11.4% | 6.07 | -3.1% | -1.5% | -5.8% | -9.7% | -8.2% | -16.8% | — |
| Mar 7, 2024 | AMC | -0.43 | -0.33 | +23.3% | 6.75 | +3.4% | -3.6% | -3.0% | -2.2% | -7.9% | -9.5% | — |
| Nov 14, 2023 | AMC | -0.39 | -0.23 | +41.0% | 2.20 | +0.5% | +0.0% | +1.8% | +4.5% | +12.3% | +7.7% | — |
| Aug 10, 2023 | AMC | -0.42 | -0.14 | +66.7% | 2.63 | +0.4% | -0.8% | -0.4% | -4.6% | +0.4% | -5.9% | — |
| May 11, 2023 | AMC | -0.50 | -0.34 | +32.0% | 2.77 | +4.0% | +6.1% | +1.4% | -1.1% | -1.1% | -1.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.65 | $0.66 | +1.8% | +6.2% | +3.5% | -2.8% | +2.1% | +1.2% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $0.92 | $0.90 | -2.1% | -0.5% | +0.6% | -7.0% | -5.0% | +6.2% |
| Aug 25 | BofA Securities | Maintains | Buy → Buy | — | $1.32 | $1.33 | +0.8% | +3.8% | +3.0% | +0.8% | +5.3% | -0.8% |
| Aug 21 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.24 | $1.21 | -2.4% | +3.2% | +6.5% | +10.5% | +9.7% | +7.3% |
| May 9 | Wedbush | Maintains | Outperform → Outperform | — | $0.87 | $0.87 | +0.0% | -8.1% | +14.9% | +17.2% | +13.8% | +27.6% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $1.26 | $1.28 | +1.6% | -2.4% | -4.0% | -4.8% | -7.1% | -7.9% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.26 | $1.28 | +1.6% | -2.4% | -4.0% | -4.8% | -7.1% | -7.9% |
| Jan 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.35 | $1.36 | +0.7% | +0.0% | +3.0% | -0.7% | -1.5% | +0.7% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.69 | -1.2% | -2.3% | -4.1% | +4.1% | +11.1% | +17.0% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.32 | -1.3% | -12.3% | -8.9% | -11.5% | -7.2% | -0.4% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.34 | $2.41 | +3.0% | +0.0% | +7.3% | +4.3% | +0.4% | -12.0% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.34 | $2.41 | +3.0% | +0.0% | +7.3% | +4.3% | +0.4% | -12.0% |
| Jun 4 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.99 | $4.16 | +4.3% | -8.8% | -10.0% | -12.3% | -12.5% | -18.5% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $4.73 | -8.5% | -22.8% | -29.6% | -30.6% | -32.3% | -32.5% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.16 | $5.10 | -1.2% | -5.4% | -3.9% | -1.4% | +3.9% | +0.2% |
| May 6 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $6.07 | $5.88 | -3.1% | -1.5% | -5.8% | -9.7% | -8.2% | -16.8% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.07 | $5.88 | -3.1% | -1.5% | -5.8% | -9.7% | -8.2% | -16.8% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.03 | $7.00 | -0.4% | -4.0% | -7.4% | -6.8% | -6.1% | -11.5% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.20 | $2.21 | +0.5% | +0.0% | +1.8% | +4.5% | +12.3% | +7.7% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.54 | +0.8% | -0.8% | -9.5% | -14.7% | +25.8% | +20.2% |
| Sep 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.44 | $2.50 | +2.5% | +4.1% | -3.3% | -7.0% | -9.6% | -17.2% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.57 | +0.0% | +0.0% | -5.1% | -1.2% | -8.2% | -11.7% |
| Aug 10 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.53 | $2.76 | +9.1% | +4.0% | +3.2% | +3.6% | -0.8% | +4.3% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.53 | $2.76 | +9.1% | +4.0% | +3.2% | +3.6% | -0.8% | +4.3% |
| Aug 9 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.54 | $2.60 | +2.4% | -0.4% | +3.5% | +2.8% | +3.1% | -1.2% |
| May 15 | BofA Securities | Maintains | Buy → Buy | — | $2.94 | $3.00 | +2.0% | -4.4% | -6.8% | -6.8% | -7.5% | -9.2% |
| May 12 | BofA Securities | Maintains | Buy → Buy | — | $2.77 | $2.88 | +4.0% | +6.1% | +1.4% | -1.1% | -1.1% | -1.8% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.04 | $3.00 | -1.3% | -8.9% | -3.3% | -7.6% | -9.9% | -9.9% |
| Mar 24 | EF Hutton | Maintains | Buy → Buy | — | $2.17 | $2.10 | -3.2% | +12.0% | +8.3% | +15.2% | +18.0% | +19.4% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.29 | $2.26 | -1.3% | -5.2% | +6.1% | +2.6% | +9.2% | +11.8% |
| Mar 23 | BofA Securities | Maintains | Buy → Buy | — | $2.29 | $2.26 | -1.3% | -5.2% | +6.1% | +2.6% | +9.2% | +11.8% |
| Feb 27 | EF Hutton | Maintains | Buy → Buy | — | $2.63 | $2.77 | +5.3% | +12.9% | +9.7% | +15.6% | -1.9% | +1.9% |
| Feb 17 | EF Hutton | Maintains | Buy → Buy | — | $3.27 | $3.33 | +1.8% | +4.9% | -5.2% | -3.4% | -6.7% | -19.6% |
| Jan 30 | BofA Securities | Maintains | Buy → Buy | — | $4.10 | $4.10 | +0.0% | +0.2% | -2.4% | -2.9% | -9.5% | -7.6% |
| Dec 5 | EF Hutton | Maintains | Buy → Buy | — | $1.77 | $1.82 | +2.8% | -1.1% | -7.9% | -13.6% | -7.3% | +1.1% |
| May 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.98 | $6.08 | +1.7% | -6.9% | -8.4% | -20.7% | -23.9% | -18.7% |
| Nov 19 | SVB Leerink | Maintains | Outperform → Outperform | — | $16.35 | $16.18 | -1.0% | -2.1% | -3.7% | -9.8% | -8.5% | -8.4% |
| Sep 10 | BofA Securities | Maintains | Buy → Buy | — | $17.50 | $18.16 | +3.8% | -2.6% | +1.0% | -2.1% | -1.1% | -1.3% |
| May 25 | Jefferies | Maintains | Buy → Buy | — | $12.18 | $12.52 | +2.8% | +5.8% | +5.3% | +20.1% | +22.2% | +13.4% |
| May 25 | SVB Leerink | Maintains | Outperform → Outperform | — | $12.18 | $12.52 | +2.8% | +5.8% | +5.3% | +20.1% | +22.2% | +13.4% |
| May 25 | Evercore ISI | Maintains | Outperform → Outperform | — | $12.18 | $12.52 | +2.8% | +5.8% | +5.3% | +20.1% | +22.2% | +13.4% |
| May 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.18 | $12.52 | +2.8% | +5.8% | +5.3% | +20.1% | +22.2% | +13.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | EVNIN LUKE | — | Sell | 79,086 | $0.63 | $50K | 1,578,749 | +9.68% | — |
| May 6, 2026 | EVNIN LUKE | — | Sell | 14,635 | $0.66 | $10K | 1,657,835 | +9.68% | — |
| May 5, 2026 | EVNIN LUKE | — | Sell | 6,860 | $0.69 | $5K | 1,672,470 | +9.68% | — |
| May 4, 2026 | EVNIN LUKE | — | Sell | 47,963 | $0.72 | $35K | 1,679,330 | -2.94% | — |
| May 1, 2026 | EVNIN LUKE | — | Sell | 58,394 | $0.73 | $43K | 1,727,293 | -2.94% | — |
| Apr 30, 2026 | EVNIN LUKE | — | Sell | 168,262 | $0.72 | $121K | 1,785,687 | -2.94% | — |
| Apr 29, 2026 | EVNIN LUKE | — | Sell | 56,559 | $0.69 | $39K | 1,953,949 | +5.82% | -4.38% |
| Apr 28, 2026 | EVNIN LUKE | — | Sell | 95,412 | $0.73 | $70K | 2,010,508 | +5.82% | -4.38% |
| Apr 27, 2026 | EVNIN LUKE | — | Sell | 53,940 | $0.85 | $46K | 2,105,920 | +5.82% | -4.38% |
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis, as the excerpt contains only standard boilerplate safe-harbor language defining forward-looking statements rather than material company news or financial information.
Mar 27
8-K
Werewolf Therapeutics, Inc. -- 8-K Filing
Werewolf Therapeutics (HOWL) has initiated a strategic review process with financial advisor Piper Sandler to explore alternatives including potential partnerships or sales to maximize shareholder value for its immune-mediated therapy pipeline.
Feb 24
8-K · 7.01
! Medium
Werewolf Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Werewolf Therapeutics (HOWL) initiated capital-raising discussions with potential investors and committed to publicly disclosing previously confidential information about its pipeline and financing plans by February 13, 2026.
Feb 13
8-K
Werewolf Therapeutics, Inc. -- 8-K Filing
Werewolf Therapeutics has received a 180-day compliance extension from Nasdaq to transfer listing to the Capital Market tier while maintaining its stock price above minimum bid requirements.
Feb 6
Data updated apr 25, 2026 1:53pm
· Source: massive.com